Sort
64,565 grants matching “drug discovery”
RP2: Targeting genes and pathways for autophagy-dependent inhibition of bacterial infection
$1,411,732Ramnik J Xavier · Ut Southwestern Medical Center · U19 · FY2023 · AI
Optimization of HIV glycoproteins as vaccine candidates
$1,411,724Jose A Lasalde-Dominicci · University Of Puerto Rico · R01 · FY2019 · AI
Strategies to Overcome Immune Resistance in Head and Neck Cancers
$1,411,624Sara Isabel Pai · Yale University · P01 · FY2023 · CA
Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1
$1,410,467Harry Bernard Greenberg · Stanford University · UL1 · FY2013 · TR
Center on Intersystem Regulation by Drugs of Abuse
$1,410,054Ellen M Unterwald · Temple Univ Of The Commonwealth · P30 · FY2018 · DA
SBIR Phase II: Resonance Force Microscopy for Nanoscale Manufacturing Process Monitoring
$1,409,994Sung I Park · Molecular Vista, Inc. · · FY2014 · TIP
SBIR Phase II: Development of a High-Throughput Drug Screening System for Eye Diseases
$1,409,979Karen Y Torrejon · Glauconix Inc. · · FY2017 · TIP
Human Trial of Allosteric Modulator Alpha7 Nicotinic Receptors in Schizophrenia
$1,409,835Robert Freedman · University Of Colorado Denver · U01 · FY2013 · MH
Bioanalysis, Drug Metabolism and New Drug Discovery
$1,409,667Josephine Egan · National Institute On Aging · ZIA · FY2015 · AG
Improving precision health approaches through large-scale EHRs and biobanks
$1,409,434Joshua Denny · National Human Genome Research Institute · ZIA · FY2023 · HG
Data Processing, Analysis and Modeling Unit
$1,409,088Peter Karl Sorger · Harvard Medical School · U2C · FY2018 · CA
Development of drugs that target the M2 proton channel from the influenza A Virus
$1,408,915William F Degrado · University Of California, San Francisco · U01 · FY2012 · AI
Discovery of Anticancer Agents of Diverse Natural Origin
$1,408,596Alan Douglas Kinghorn · Ohio State University · P01 · FY2022 · CA
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients
$1,408,317Pasi A Janne · Dana-Farber Cancer Inst · U01 · FY2016 · HG
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients
$1,408,317Pasi A Janne · Dana-Farber Cancer Inst · U01 · FY2015 · HG
Examining Gut Microbiome as a Determinant of Blueberry Polyphenol Bioavailability to Optimize Dose and Phytochemical Standardization for Functional Effects in Humans
$1,407,811Tiffany L Weir · Colorado State University · RM1 · FY2025 · AT
Molecular Analyses of Endometrial Cancer
$1,407,810Daphne Bell · National Human Genome Research Institute · ZIA · FY2025 · HG
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,407,704David E Fisher · Massachusetts General Hospital · P01 · FY2016 · CA
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,407,704David E Fisher · Massachusetts General Hospital · P01 · FY2017 · CA
NX90: A Treatment for Overdose Caused by High Potency Opioids
$1,407,382Michael V. Voronkov · Serodopa Therapeutics Inc · R44 · FY2025 · DA
Coordinating Center for the Drug Induced Liver Injury Network (DILIN)
$1,407,208Huiman X Barnhart · Duke University · U24 · FY2020 · DK
High throughput infrastructure for reaction screening and bioassays
$1,407,199Robert Graham Cooks · Purdue University · UH3 · FY2024 · TR
Coordinating Center for the Drug Induced Liver Injury Network (DILIN)
$1,407,155Huiman X Barnhart · Duke University · U24 · FY2021 · DK
Center on Intersystem Regulation by Drugs of Abuse
$1,406,934Ellen M Unterwald · Temple Univ Of The Commonwealth · P30 · FY2017 · DA
Center on Intersystem Regulation by Drugs of Abuse
$1,406,934Ellen M Unterwald · Temple Univ Of The Commonwealth · P30 · FY2019 · DA